Skip to Content

Virtus LifeSci Biotech Products ETF BBP

Quantitative rating as of | See Virtus Investment Hub

Morningstar’s Analysis BBP

Will BBP outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.



Weakness in Virtus LifeSci Biotech Products ETF's Process and People Pillar ratings limits this strategy to a Morningstar Quantitative Rating of Negative. The strategy charges fees in line with its similarly distributed peers, priced within the middle quintile.

Unlock our full analysis with Morningstar Investor